Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ying-Xia Zhou

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Acta Crystallographica. Section E, Structure Reports Online|May 18, 2011
(E)-N'-(1,3-Benzodioxol-5-ylmethyl-ene)nicotinohydrazide monohydrateFeng-Yu Bao, Hai-Yan Zhang, Ying-Xia Zhou, et al.
Acta Crystallographica. Section E, Structure Reports Online|May 18, 2011
(E)-N'-(3,4-Dichloro-benzyl-idene)nicotino-hydrazide monohydrateFeng-Yu Bao, Ying-Xia Zhou, Hai-Yan Zhang, et al.
Acta Crystallographica. Section E, Structure Reports Online|May 18, 2011
N'-(3-Bromo-4-methoxy-benzyl-idene)nicotinohydrazide monohydrateFeng-Yu Bao, Xing-Shun Ding, Hai-Yan Zhang, et al.
Acta Crystallographica. Section E, Structure Reports Online|May 18, 2011
N'-(Propan-2-yl-idene)nicotinohydrazideFeng-Yu Bao, Yu-Xia Zhang, Ying-Xia Zhou, et al.
Cell Death Discovery|May 18, 2022
METTL3-mediated macrophage exosomal NEAT1 contributes to hepatic fibrosis progression through Sp1/TGF-β1/Smad signaling pathwayBo Shu, Rui-Zhi Zhang, Ying-Xia Zhou, et al.
Cell Death Discovery|November 28, 2021
The METTL3/MALAT1/PTBP1/USP8/TAK1 axis promotes pyroptosis and M1 polarization of macrophages and contributes to liver fibrosisBo Shu, Ying-Xia Zhou, Hao Li, et al.
Frontiers in Immunology|December 18, 2025
Gemcitabine-cisplatin chemotherapy plus anti-PD-L1 therapy reinvigorates antitumor immune response by reprogramming the intrahepatic cholangiocarcinoma microenvironmentYang Song, Shao-Wei Huang, Bo Shu, et al.
Frontiers in Immunology|December 29, 2025
Enhancing cDC1-mediated anti-tumor immunity limits tumor progression and potentiates anti-PD-1 therapy in intrahepatic cholangiocarcinomaDong-Ni Pei, Yang Song, Ying-Xia Zhou, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Acta Crystallographica. Section E, Structure Reports Online|May 18, 2011
(E)-N'-(1,3-Benzodioxol-5-ylmethyl-ene)nicotinohydrazide monohydrateFeng-Yu Bao, Hai-Yan Zhang, Ying-Xia Zhou, et al.
Acta Crystallographica. Section E, Structure Reports Online|May 18, 2011
(E)-N'-(3,4-Dichloro-benzyl-idene)nicotino-hydrazide monohydrateFeng-Yu Bao, Ying-Xia Zhou, Hai-Yan Zhang, et al.
Acta Crystallographica. Section E, Structure Reports Online|May 18, 2011
N'-(3-Bromo-4-methoxy-benzyl-idene)nicotinohydrazide monohydrateFeng-Yu Bao, Xing-Shun Ding, Hai-Yan Zhang, et al.
Acta Crystallographica. Section E, Structure Reports Online|May 18, 2011
N'-(Propan-2-yl-idene)nicotinohydrazideFeng-Yu Bao, Yu-Xia Zhang, Ying-Xia Zhou, et al.
Cell Death Discovery|May 18, 2022
METTL3-mediated macrophage exosomal NEAT1 contributes to hepatic fibrosis progression through Sp1/TGF-β1/Smad signaling pathwayBo Shu, Rui-Zhi Zhang, Ying-Xia Zhou, et al.
Cell Death Discovery|November 28, 2021
The METTL3/MALAT1/PTBP1/USP8/TAK1 axis promotes pyroptosis and M1 polarization of macrophages and contributes to liver fibrosisBo Shu, Ying-Xia Zhou, Hao Li, et al.
Frontiers in Immunology|December 18, 2025
Gemcitabine-cisplatin chemotherapy plus anti-PD-L1 therapy reinvigorates antitumor immune response by reprogramming the intrahepatic cholangiocarcinoma microenvironmentYang Song, Shao-Wei Huang, Bo Shu, et al.
Frontiers in Immunology|December 29, 2025
Enhancing cDC1-mediated anti-tumor immunity limits tumor progression and potentiates anti-PD-1 therapy in intrahepatic cholangiocarcinomaDong-Ni Pei, Yang Song, Ying-Xia Zhou, et al.
Pageof 1